Abstract:Background: Poor graft function (PGF) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the mechanisms underlying PGF remain to be elucidated, which increases the difficulty of managing PGF. In murine study, effective cross-talk between hematopoietic stem cells (HSCs) and bone marrow (BM) micro-environment plays an important role in hematopoiesis. HSCs occupy a hypoxic BM micro-environment to protect them from oxidative stress, whereas excessive reactive oxygen species (ROS) could inhibit HSCs self-renewal and induce HSCs exhaustion resulting in hematopoietic dysfunction. We recently reported that the impaired BM micro-environment may contribute to the occurrence of PGF post-HSCT using a prospective nested case-control study (Kong Y, et al. Biol Blood Marrow Transplant. 2013;19:1465-1473). Nevertheless, it is largely unknown whether the quantitatively and functionally impaired HSCs pre- and post-HSCT operate in the occurrence of PGF in allotransplants patients. Aims: To investigate whether the quantitative and functional abnormalities of the donor BM CD34 + cells pre- and post-HSCT are involved in the pathogenesis of PGF. Methods: The hematopoietic reconstitution activities of the CD34 + cells, sorted from the donors9 BM of PGF and good graft function (GGF) patients, were evaluated in xenografted NOD-Prkdc scid IL2rg null mice as an indicator of donors9 HSCs function. To further investigate the effect of oxidative stress on normal hematopoiesis post-HSCT, the BM CD34 + cells of GGF allotransplant patients were treated of hydrogen peroxide (H 2 O 2 ) with or without antioxidant N-acetyl-L-cysteine (NAC) in vitro. Subsequently, a prospective nested case-control study was performed enrolling 15 patients with PGF, 30 matched patients with GGF after allo-HSCT and their healthy donors. Quantification of the frequency, intracellular ROS levels, and cell cycle status of the BM CD34 + cells were analyzed by flow cytometry pre- and post-HSCT. Colony-forming capacity was investigated in CD34 + cells post-HSCT in vitro. The study was approved by the Ethics Committee of Peking University People9s Hospital and written informed consent was obtained from all subjects. Results: The hematopoietic reconstitution activity of the BM CD34 + cells in NOD-Prkdc scid IL2rg null mice demonstrated no significant differences between the donors of PGF and GGF patients. In the subsequent in vitro study, increased ROS were found to play an important role in the exhaustion of the quiescent BM CD34 + cells of GGF patients, whereas treatment of ROS-abrogated CD34 + cells with the antioxidant NAC could partially, but significantly restore the exhaustion and colony-forming capacity of CD34 + cells. In the prospective nested case-control study, all patient- and therapy-related variables were similar between patients with PGF and GGF. Polymerase chain reaction DNA fingerprinting of the STRs confirmed 100% donor chimerism in these patients. The frequency, intracellular ROS levels and cell cycle status of the transplanted donor BM CD34 + cells showed no remarkable differences pre-HSCT. Nevertheless, the percentage of CD34 + cells post-HSCT and their colony-forming capacity, especially the quiescent CD34 + CD38 low fraction, decreased remarkably in PGF patients when compared to that in GGF patients. Notably, significantly increased ROS levels were observed in CD34 + and CD34 + CD38 low fractions of PGF patients post-HSCT. Summary/Conclusion: Although the frequency and function of the transplanted donor BM CD34 + cells of PGF were demonstrated normal pre-HSCT, the increased levels of ROS and exhaustion of the quiescent CD34 + cells may operate in PGF post-HSCT. Our preliminary data indicate that an impaired BM micro-environment which may hamper the hematopoietic reconstitution of the donor HSCs in the recipients, rather than the defective donor HSCs, was involved in the occurrence of PGF. Therefore, novel therapeutic approaches, such as antioxidative therapy to maintain hypoxia BM micro-environment, promise to facilitate hematopoietic recovery in PGF. Acknowledgement: Supported by the National Natural Science Foundation of China (grant nos. 81370638u002681230013), and the Beijing Municipal Science and Technology Program (grant nos. Z141100000214011u0026 Z151100004015164u0026 Z151100001615020). Disclosures No relevant conflicts of interest to declare.

Cd34(+) Cells In Bone Marrow Are Quantitatively And Functionally Impaired In Patients With Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

An Unbalanced Monocyte Macrophage Polarization In The Bone Marrow Microenvironment Of Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants.

Increased Levels of Reactive Oxygen Species and Exhaustion of the Quiescent CD34 + Cells May Operate in Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation

Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant.

Abnormalities Of The Bone Marrow Immune Microenvironment In Patients With Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation.

Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation

Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function

Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights☆

Dysregulated T Cell Response in Bone Marrow Immune Micro-Environment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation

The efficacy and safety of recombinant human granulocyte colony stimulating factor primed donor peripheral cell harvest in treatment of poor graft function after allogeneic stem cell transplantation

P1249: insufficient pparδ in bone marrow endothelial progenitor cells leads to their impaired hematopoiesis-supporting ability

The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation

[Efficacy of donor's purified CD34(+) cells for treatment of poor graft function following allogeneic hematopoietic stem cell transplantation].

“Back-Up” Stem Cell Harvest is Beneficial for Patients Receiving Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.

S894 DEFECTIVE GLYCOLYSIS IN BONE MARROW ENDOTHELIAL CELLS OF PATIENTS WITH POOR GRAFT FUNCTION POST‐ALLOTRANSPLANT IDENTIFIES A POTENTIAL THERAPEUTIC STRATEGY

Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation